These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25816642)

  • 1. [Acinetobacter: microbiological, pathogenetic and resistant properties].
    Chebotar IV; Lazareva AV; Masalov YK; Mikhailovich VM; Mayanskiy NA
    Vestn Ross Akad Med Nauk; 2014; (9-10):39-50. PubMed ID: 25816642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.
    Wong D; Nielsen TB; Bonomo RA; Pantapalangkoor P; Luna B; Spellberg B
    Clin Microbiol Rev; 2017 Jan; 30(1):409-447. PubMed ID: 27974412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial resistance of Acinetobacter spp. in Europe.
    Van Looveren M; Goossens H;
    Clin Microbiol Infect; 2004 Aug; 10(8):684-704. PubMed ID: 15301671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acinetobacter infections in patients with human immunodeficiency virus infection: microbiological and clinical epidemiology.
    Manfredi R; Nanetti A; Valentini R; Chiodo F
    Chemotherapy; 2001; 47(1):19-28. PubMed ID: 11125229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug-resistant Acinetobacter baumannii.
    Krcmery V; Kalavsky E
    Emerg Infect Dis; 2007 Jun; 13(6):943-4. PubMed ID: 17582898
    [No Abstract]   [Full Text] [Related]  

  • 6. Multidrug-resistant Acinetobacter: a threat to the antibiotic era.
    Peleg AY; Paterson DL
    Intern Med J; 2006 Aug; 36(8):479-82. PubMed ID: 16866649
    [No Abstract]   [Full Text] [Related]  

  • 7. Bloodstream infections caused by Acinetobacter species with reduced susceptibility to tigecycline: clinical features and risk factors.
    Park GE; Kang CI; Cha MK; Cho SY; Seok H; Lee JH; Kim JY; Ha YE; Chung DR; Peck KR; Lee NY; Song JH
    Int J Infect Dis; 2017 Sep; 62():26-31. PubMed ID: 28676346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single clone of Acinetobacter baumannii, ST22, is responsible for high antimicrobial resistance rates of Acinetobacter spp. isolates that cause bacteremia and urinary tract infections in Korea.
    Park YK; Lee GH; Baek JY; Chung DR; Peck KR; Song JH; Ko KS
    Microb Drug Resist; 2010 Jun; 16(2):143-9. PubMed ID: 20370437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ecology, biology and pathogenesis of Acinetobacter spp.: an overview.
    Doughari HJ; Ndakidemi PA; Human IS; Benade S
    Microbes Environ; 2011; 26(2):101-12. PubMed ID: 21502736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenic Acinetobacter: from the Cell Surface to Infinity and Beyond.
    Weber BS; Harding CM; Feldman MF
    J Bacteriol; 2015 Dec; 198(6):880-7. PubMed ID: 26712938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial Resistance in
    Lupo A; Haenni M; Madec JY
    Microbiol Spectr; 2018 Jun; 6(3):. PubMed ID: 30101740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acinetobacter pittii isolated more frequently than Acinetobacter baumannii in blood cultures: the experience of a French hospital.
    Pailhoriès H; Tiry C; Eveillard M; Kempf M
    J Hosp Infect; 2018 Jul; 99(3):360-363. PubMed ID: 29577994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bacteria of the genus Acinetobacter: clinical significance and therapy of infections].
    Wróblewska M
    Pneumonol Alergol Pol; 2006; 74(2):227-31. PubMed ID: 17269375
    [No Abstract]   [Full Text] [Related]  

  • 14. Acinetobacter spp in a Third World Country with Socio-economic and Immigrants Challenges.
    Dandachi I; Azar E; Hamouch R; Maliha P; Abdallah S; Kanaan E; Badawi R; Khairallah T; Matar GM; Daoud Z
    J Infect Dev Ctries; 2019 Nov; 13(11):948-955. PubMed ID: 32087065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tigecycline treatment in an infant with extensively drug-resistant Acinetobacter baumannii bacteremia.
    Zeng J; Zhang L; Gao M; Wu J; Wu H; Chen J; Chen X; Tang W
    Int J Infect Dis; 2017 Aug; 61():23-26. PubMed ID: 28572073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors and outcomes of bloodstream infections with metallo-beta-lactamase-producing Acinetobacter.
    Kim YA; Choi JY; Kim CK; Kim CO; Kim MS; Choi SH; Chin BS; Han SH; Lee HS; Choi HK; Jeoung SJ; Song YG; Yum JH; Yong D; Lee K; Kim JM
    Scand J Infect Dis; 2008; 40(3):234-40. PubMed ID: 17852898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features.
    Bergogne-Bérézin E; Towner KJ
    Clin Microbiol Rev; 1996 Apr; 9(2):148-65. PubMed ID: 8964033
    [No Abstract]   [Full Text] [Related]  

  • 18. Acinetobacter infection in the ICU.
    Murray CK; Hospenthal DR
    Crit Care Clin; 2008 Apr; 24(2):237-48, vii. PubMed ID: 18361943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The increasing significance of outbreaks of Acinetobacter spp.: the need for control and new agents.
    Bergogne-Bérézin E
    J Hosp Infect; 1995 Jun; 30 Suppl():441-52. PubMed ID: 7560983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the virulence potential of Acinetobacter strains from clinical and environmental sources.
    Tayabali AF; Nguyen KC; Shwed PS; Crosthwait J; Coleman G; Seligy VL
    PLoS One; 2012; 7(5):e37024. PubMed ID: 22655033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.